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The ANP knockout mouse is reported to exhibit pregnancy-associated hypertension, proteinuria and
impaired placental trophoblast invasion and spiral artery remodeling, key features of pre-eclampsia (PE).
We hypothesized that these mice may provide a relevant model of human PE with associated fetal
growth restriction (FGR). Here, we investigated pregnancies of ANP wild type (ANPþ/þ), heterozygous
(ANPþ/-) and knockout (ANP/-) mice. Maternal blood pressure did not differ between genotypes (E12.5,
E17.5), and fetal weight (E18.5) was unaffected. Placental weight was greater in ANP/ versus ANPþ/þ
mice. Therefore, in our hands, the ANP model does not express phenotypic features of PE with FGR.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Pre-eclampsia (PE), the leading cause of maternal and perinatal
morbidity andmortality worldwide, affects 3e5% of all pregnancies
[1]. PE is characterized by the onset of hypertension and protein-
uria, from 20 weeks gestation [2], and is associated with placental
dysfunction and widespread maternal vascular endothelium acti-
vation [3,4] leading to the pathophysiology of multi-system organ
dysfunction. To date, there are no treatments for PE, the only
effective intervention being premature delivery of the baby [5e7].
The development of clinically relevant mouse models of human
pregnancy complications such as PE and fetal growth restriction
(FGR) is essential for furthering our understanding of these con-
ditions and for testing potential therapies [8]. Despite the fact that,
in humans, PE is the leading cause of FGR [9], to our knowledge
there remain no reports of a genetically modiﬁed mouse that
demonstrates PE with FGR.
Atrial natriuretic peptide (ANP) plays a key role in blood pres-
sure regulation and sodium homeostasis [10,11]. Previous studies
have reported that adult male ANP knockout (ANP/-) mice are
hypertensive compared with wildtype (ANPþ/þ) counterparts,(S.L. Finn-Sell).
r Ltd. This is an open access articlewhilst heterozygous animals (ANPþ/-) display an intermediate
phenotype, becoming hypertensive only after receiving a high salt
diet [12]. More recently, Cui et al. demonstrated that adult female
ANP/ mice exhibit pre-pregnancy hypertension, with further
systolic blood pressure increases during pregnancy and associated
late gestation proteinuria [13]. Pregnant ANP/ mice also had
signiﬁcantly reduced litter sizes compared with their ANPþ/þ
counterparts, although fetal weight was not reported [13]. Here, we
tested the hypothesis that ANP/ mice exhibit FGR in addition to
phenotypic features of PE.2. Methods
2.1. Animals
Animal care and experimental procedures were performed in
accordance with the U.K. Animals (Scientiﬁc Procedures) Act 1986.
ANP mice (strain: B6.129P2-Nppatm1Unc/J), were obtained from
Jackson Laboratories and the colony was maintained as heterozy-
gous breeding pairs. Experimental animals of each genotype (ANPþ/
þ, ANPþ/ and ANP/-) were mated in genotype-matched pairs; the
presence of a copulation plug was designated as embryonic day (E)
0.5 of pregnancy. Animals had food (Beekay Rat and Mouse Diet;
Bantin & Kingman, UK) and water ad libitum, and were maintainedunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Systolic blood pressure and proteinuria during pregnancy. (A) Systolic blood pressure was not signiﬁcantly different between ANPþ/þ (n ¼ 5) and ANP/ (n ¼ 5) dams either
pre-pregnancy (non-pregnant; NP) or at E12.5 or E17.5 by two-way ANOVA. Systolic blood pressure did not increase in pregnancy in either genotype. Data are mean ± SD. (B) ANP/
 mice did not demonstrate proteinuria at E18.5. Lines represent median, n ¼ 7e8.
Fig. 2. Fetal and placental weight at E18.5. (A) Placental weight was signiﬁcantly increased in ANP/ fetuses from ANP/ x ANP/ mating pairs compared with ANPþ/þ from
ANPþ/þ x ANPþ/þmatings; one-way ANOVA, *P < 0.05. ANP animals of all three genotypes from ANPþ/ x ANPþ/matings (Het x) were not different from either ANP/ x ANP/ or
ANPþ/þ x ANPþ/þ offspring. (B) There was no difference in fetal weight between genotypes. Data are litter means (n ¼ 12e15 litters). (C) There was no increase in the number of
ANP/ fetuses falling below the 5th centile of ANPþ/þ fetal weights (Data from ANPþ/þ x ANPþ/þ and ANP/ x ANP/ matings, n ¼ 109 ANPþ/þ n ¼ 75 ANP/ fetuses.
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ear clips (offspring, at weaning) or fetal tail tips for genotype
determination (primers and PCR conditions available on request).
Blood pressure was measured using a previously validated tail-
cuff method (LE5001; Pan Lab, Spain, [14]). Systolic blood pressure
(SBP) measurements were made in non-pregnant mice (2e4 days
pre-mating) and subsequently in pregnant mice (E12.5 and E17.5).
At E18.5, fetuses and placentas were rapidly harvested and wet
weights recorded. Fetal weight centile charts were constructed as
previously described [15].
2.2. Urine albumin and creatinine concentration
Maternal urine was collected at E18.5 by spontaneous voiding
and aliquoted and stored at20 C. Urinary albumin (mouse ELISA;
AssayPro, St Charles, MO), and creatinine (Cayman Chemical
Company, Ann Arbour, MI) concentration was measured and the
albumin/creatinine ratio calculated.
2.3. Statistical analysis
Data are presented as mean ± SD or dot plots of litter means
with median. Statistical analysis was by two-way ANOVA or
Kruskal-Wallis test as appropriate. P < 0.05 was deemed signiﬁcant.
3. Results and discussion
In contrast to previous reports [13,16], neither ANP/, nor
ANPþ/ dams demonstrated a hypertensive phenotype either
before or during pregnancy (Fig 1A). Indeed, the SBP values for all
dams obtained in the present study were comparable to that of our
C57Bl/6J mice, the ANP model's background strain (E17.5 SBP of
116.5 ± 3.9 mmHg, n ¼ 6). This discrepancy between observations
from different laboratories may be due to methodological differ-
ences e.g. use of radiotelemetry compared with tail cuff technique
employed here. However, it is important to note that the ﬁrst paper
describing the phenotype of ANP/ animals, which used a similar
tail cuff technique to our own, showed only relatively minor dif-
ferences in SBP unless animals were challenged with a high-salt
diet [12]. Furthermore, it is unlikely a deﬁciency in the tail cuff
technique used, as our contemporaneous measurements from
pregnant eNOS/ mice (an established model of hypertension,
[17e19]) demonstrated signiﬁcantly elevated SBP in this model
(E17.5, 136.0 ± 8.7 mmHg, n ¼ 6).
Concomitant with a lack of raised SBP, there was no evidence of
proteinuria in ANP/ compared with ANPþ/þ dams (Fig 1B). We
also found no reduction in litter size from ANP/ mice (median
litter size 7 (range 5e11) pups per litter) comparedwith litters from
ANPþ/ and ANPþ/þ dams (8 (5e10) and 9 (5e11) pups per litter,
respectively). However, within our colony we observed fewer
ANP/ offspring surviving to weaning, with only 9.8% (17/174) of
total female offspring and 13.5% (23/171) of total male offspring
being ANP/. In contrast, the fetal genotypes in the ANPþ/ litters
at E18.5 approximated an expected Mendelian ratio (24% ANP/,
43% ANPþ/ and 35% ANPþ/þ). This suggests that the ANP/
offspring have an increased risk of neonatal mortality, although the
reasons for this are currently unknown.
No differences were observed in fetal weight between ANP/
(from ANP/ homozygous matings) and ANPþ/þmice (Fig. 2B) and
there was no signiﬁcant difference in the number of fetuses falling
below the 5th percentile (deﬁned as FGR, [15]), strengthening the
assertion that ANP deletion does not cause FGR. Indeed, there was a
non-signiﬁcant rightward shift of the growth curve of ANP/ fe-
tuses, which may be related to oedema, which was apparent in a
number of fetuses (data not shown). Similarly, placental wet weightwas signiﬁcantly greater in ANP/ compared to ANPþ/þ fetuses
(Fig. 2A, P < 0.01).
In summary, we ﬁnd that deletion of the ANP gene in mice is
associated with increased placental weight and a failure to thrive in
the neonatal period, but not with phenotypic features of PE or FGR.
These data reinforce the need to identify robust animal models of
pregnancy complications in which to test candidate therapeutics,
and the importance of fully characterizing animal models in inde-
pendent laboratories before they can be established for use in ob-
stetric research.
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